Founded by Dr Misti Ushio and headquartered in New York, Tara Biosystems is a human heart-on-a-chip company which has developed a proprietary platform to generate novel cardiac tissue models.
Through these physiologically human-relevant predictive models, the company offers a variety of solutions that can decisively evaluate the efficacy and risk of novel medicines, helping to reduce the time and cost of the drug discovery and development process.
Through these physiologically human-relevant predictive models, the company offers a variety of solutions that can decisively evaluate the efficacy and risk of novel medicines, helping to reduce the time and cost of the drug discovery and development process.
Total raised: $12.25M
Investors 5
| Date | Name | Website |
| - | Merieux De... | merieux-pa... |
| - | Lifeforce ... | lifeforcec... |
| - | Tachyon Ve... | tachyon.vc |
| - | OMX Ventur... | omx.vc |
| - | Korys | korys.be |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 23.06.2020 | - | $10M | - |
| 08.01.2016 | Seed | $2.25M | - |
Mentions in press and media 9
| Date | Title | Description |
| 23.06.2020 | TARA Biosystems Announces $10 Million Series A2 Financing | NEW YORK--(BUSINESS WIRE)--TARA Biosystems, Inc., a company generating in vitro human biology to increase the success of cardiac disease drug discovery and development, today announced a $10 million Series A2 financing. This financing will ... |
| 23.06.2020 | TARA Biosystems Raises $10M Series A2 | NEW YORK, NY, TARA Biosystems today announced a $10 million Series A2 financing. >> Click here for more funding data on TARA Biosystems >> To export TARA Biosystems funding data to PDF and Excel, click here TARA Biosystem... |
| 23.06.2020 | Tara Biosystems Raises $10M in Series A2 Financing | Tara Biosystems, Inc., a NYC-based vitro human biology company, raised $10m in Series A2 financing. Backers included new investors OMX Ventures, Merieux Equity Partners, and LifeForce Capital and current investors Alexandria Venture Investm... |
| 17.05.2018 | UPMC, Philips, AHA, form new fund targeting cardiovascular treatment innovations | Nancy Brown, American Heart Association CEO said in the statement that the collaborative investment approach was one way to address the escalating costs of cardiovascular treatment, which the AHA projects will teeter into the $1 trillion ra... |
| 18.04.2017 | Thirteen new women-led healthcare startups join Springboard’s Health Innovation Hub | “We recently began to tell our story at various Med/Biotech conferences and startup challenges,” explained Singh via email. “We have to approach it judiciously and strategically and, frankly, we need a little guidance on how to navigate our... |
| 08.01.2016 | Tara Biosystems Raises $2.25M in Seed Funding | Tara Biosystems, Inc., a NYC-based provider of physiologically-relevant “heart-on-a-chip” tissue models for both toxicology and drug discovery applications, raised $2.25m in seed funding. The round was led by Harris & Harris Group with ... |
| - | Thirteen new women-led healthcare startups join Springboard’s Health Innovation Hub | A new batch of 13 women-led life science and healthcare startups have been accepted into Springboard Enterprises’ Health Innovation Hub, a year-long program for growth-stage companies preparing to expand and raise funds for new product deve... |
| - | UPMC, Philips, AHA, form new fund targeting cardiovascular treatment innovations | University of Pittsburgh Medical Center, Philips, and the American Heart Association have banded together to start venture capital fund, Cardeation Capital. The $30 million fund, which will be managed by healthcare investment firm Aphelion ... |
| - | TARA Biosystems Raises $10M to Grow Human Tissue Outside of the Body to Aid in the Development of New Drugs | 626SHARES FacebookTwitter Linkedin The average time to get a drug to market, crossing FDA hurdles, is 12 years and costs in excess of $1B. TARA Biosystems has developed breakthrough technology to generate human tissue outside of the body th... |